Vaccines Enabling HIV Prevention Targeting Germinal Center Enhancement with Engineered Slow Release Nanoparticles

通过工程缓释纳米颗粒增强生发中心来预防艾滋病毒的疫苗

• 批准号: 10213497
• 负责人: SILVIA GRAMA
• 金额: $ 30万
• 依托单位: NANOCOMPOSIX, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10213497
• 关键词: AIDS prevention; Address; Adjuvant; Affinity; Antibody Response; Antigen Targeting; Antigens; Attention; Chitosan; Confocal Microscopy; Development; Engineering; Flow Cytometry; HIV; HIV envelope protein; HIV vaccine; Immune response; Messenger RNA; Nucleic Acids; Nucleosome Core Particle; RNA; Research; Structure of germinal center of lymph node; Surface; Vaccine Research; Vaccines; base; design; env Gene Products; ex vivo imaging; in vivo imaging; lymph nodes; monomer; nanoparticle; nanoparticle delivery; neutralizing antibody; next generation; particle; prophylactic; response; trafficking

Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen design and soluble antigens, the targeted and controlled delivery of antigens has not received much attention and is a gap in the HIV field that needs to be addressed. Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, selfamplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies.

基于粒子的 HIV 免疫原共同递送作为下一代 HIV 疫苗：HIV 疫苗研究的一个主要焦点是开发能够引发针对包膜蛋白 (Env) 的广泛中和抗体反应的免疫原。虽然该领域主要集中在免疫原设计和可溶性抗原上，但抗原的靶向和控制递送尚未受到太多关注，并且是 HIV 领域需要解决的空白。定制的免疫原（例如Env、单体、天然和/或类似天然的三聚体、核酸/RNA，例如mRNA、自扩增RNA）与用于递送的纳米颗粒上的有效多价抗原展示相结合，可以提供一种促进强而长期免疫原的策略。存在针对 HIV 的中和抗体反应以及对 HIV 中和抗体的直接亲和力成熟。